The Company’s scientific excellence is reflected in its proprietary PI3K and HDAC6 inhibitor programmes, from which innovative small molecule drugs with significant clinical and commercial potential have been developed.
The UK-based Company is privately-held with a strong financial track record and experienced investors including SV Life Sciences, New Leaf Ventures, Novo A/S and IP Group.
Karus Therapeutics is led by a strong management team with considerable experience of building, developing and partnering therapeutic assets in Europe and North America.
Chief Executive Officer
"Karus is dedicated to developing innovative therapeutics to treat chronic inflammatory disease and cancer. Our goal is to demonstrate the clinical potential of our PI3K and HDAC6 inhibitors and secure the right commercialisation partners to ensure that the company's shareholders get the best possible return on their investment."